Please assess the completion status of the following clinical trial:

Trial Title: A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-Small Cell Lung Cancer disease~* Clinical stage IV or recurrent disease~* One prior first-line platinum-based chemotherapy regimen with or without maintenance therapy~* For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization~* For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy (only one regimen in the setting of single use) should be utilized~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1~* Adequate organ function~* Estimated life expectancy of at least 3 months.~Exclusion Criteria:~* Have undergone major surgery within 28 days prior to randomization or have planned major surgery during study treatment~* Receiving concurrent treatment with other anticancer therapy~* Central nervous system disease other than stable and treated brain metastasis~* Has major blood vessel invasion or encasement by cancer~* Has intratumor cavitation~* Has a history of uncontrolled thrombotic disorder~* Is receiving therapeutic anticoagulation with drugs~* Is receiving chronic therapy with nonsteroidal anti-inflammatory drugs~* Has a history of hemoptysis within 2 months prior to randomization~* Has clinically relevant congestive heart failure~* Has experienced any arterial thromboembolic event~* Has uncontrolled arterial hypertension~* Has had a serious or nonhealing wound or, ulcer~* Has significant existing conditions

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramucirumab plus Docetaxel (Type: EXPERIMENTAL): Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
- Placebo plus Docetaxel (Type: PLACEBO_COMPARATOR): Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).